-
1.发明授权Recombinant proteins of a pakistani strain of hepatitis E and their use in diagnostic methods and vaccines 失效戊型肝炎病毒的重组蛋白及其在诊断方法和疫苗中的应用
公开(公告)号：US6054567A
公开(公告)日：2000-04-25
申请号：US840316
申请日：1997-04-11
IPC分类号： G01N33/576 , A61K38/00 , A61K39/00 , A61K39/29 , A61P1/16 , A61P31/20 , C07K14/08 , C07K16/10 , C12N5/10 , C12N15/09 , C12N15/51 , C12P21/02 , C12N15/11 , C12N15/00 , C12N15/63 , C12Q1/70
CPC分类号： C07K14/005 , A61K39/00 , C12N2770/28122 , G01N2333/08
摘要： The invention relates to the expression of open reading frame 2 (ORF-2) proteins of a strain of hepatitis E virus from Pakistan (SAR-55) in a eukaryotic expression system. The expressed proteins can serve as an antigen in diagnostic immunoassays and/or as an immunogen or vaccine to protect against infection by hepatitis E.
摘要翻译： 本发明涉及在真核表达系统中来自巴基斯坦（SAR-55）的乙型肝炎病毒株的开放阅读框2（ORF-2）蛋白的表达。 表达的蛋白质可以用作诊断免疫测定中的抗原和/或作为免疫原或疫苗以防止乙型肝炎的感染。
-
2.发明授权Recombinant plasmid DNA pVN 22 coding biosynthesis of human leukocyte interferon alpha-I1 and strain Pseudomonas sp. 31 (pVN 22) - producer of human leukocyte interferon alpha-I1 containing same 失效编码人白细胞干扰素α-I1和菌株假单胞菌属的生物合成的重组质粒DNA pVN 22。 31（pVN 22） - 包含其的人白细胞干扰素α-I1的生产者
公开(公告)号：US4988622A
公开(公告)日：1991-01-29
申请号：US163967
申请日：1987-12-15
申请人： Jury I. Kozlov , Vera A. Nardoditskaya , Marina R. Eremashvili , Alexander Y. Strongin , Viktor E. Sterkin , Marina A. Skvortsova , Andrei J. Chistoserdov , Jury D. Tsygankov , Ljudmila V. Evdonina , Vitaly L. Jurin , Galina S. Monastyrskaya , Evgeny D. Sverdlov , Grigory M. Dolganov , Sergei A. Tsarev
发明人： Jury I. Kozlov , Vera A. Nardoditskaya , Marina R. Eremashvili , Alexander Y. Strongin , Viktor E. Sterkin , Marina A. Skvortsova , Andrei J. Chistoserdov , Jury D. Tsygankov , Ljudmila V. Evdonina , Vitaly L. Jurin , Galina S. Monastyrskaya , Evgeny D. Sverdlov , Grigory M. Dolganov , Sergei A. Tsarev
IPC分类号： C12N15/09 , A61K38/21 , C07H21/04 , C07K14/56 , C12N1/20 , C12N1/21 , C12N15/00 , C12N15/21 , C12N15/78 , C12P21/00 , C12R1/38
摘要： A recombinant plasmid DVA pVN22 coding the biosynthesis of a human leukocyte interferon .alpha.-I1 having size of 10.85 t.p.b. and consisting of the following units:EcoRI--HindIII--a fragment of the plasmid pAYC37 with the size of 9.45 t.p.b.,HindIII--EcoRI--a fragment with the size of 1.4 t.p.b. consisting of the following members:a fragment of DNA with the size of 0.25 t.p.b. with the regulatory range of gene D of the phague .phi..times.174 and the first codons of the gene of interferongene of interferon .alpha.-I1 with the size of 0.5 t.p.b.,a region of the human genome DNA with the size of 0.65 t.p.b.;it has the following genetic markers: genome Ap.sup.R ensuring resistance against ampicillin, genome Sm.sup.R ensuring resistance to streptomycin; contains unique regions of recognition of restrictases: Hind III--O; EcoRI--1.4 t.p.b., BamHI--10.82 t.p.b., it is deposited at the collection of culture of microogranisms of the A11-Union Research Institute of Antibiotics and registered under the entry No. 1788.sup.I.A strain Pseudomonas Sp. 31 (pVN22)--producer of a human leukocyte interferon .alpha.-I1 containing a recombinant plasmid DNA pVN22 produced by the method of genetic engineering by introducing said plasmid into bacteria of the genus Pseudomonas, deposited at the collection of cultures of microoorganisms of the A11-Union Research Institute of Antibiotics on 02.04.86 and registered under the entry No. 1788A.
摘要翻译： PCT No.PCT / SU87 / 00052 Sec。 371日期：1987年12月15日 102（e）日期1987年12月15日PCT 1987年4月29日PCT PCT。 公开号WO87 / 06613 日期为1987年11月5日。重组质粒DVA pVN22，其编码大小为10.85t.p.b的人白细胞干扰素α-1的生物合成。 并由以下单元组成：EcoRI-HindIII-大小为9.45t.p.b的质粒pAYC37的片段，HindIII-EcoRI-一个大小为1.4t.p.b的片段。 由以下成员组成：大小为0.25 t.p.b的DNA片段。 具有phague x174的基因D的调节范围和大小为0.5t.p.b的干扰素α-1的干扰素基因的基因的第一个密码子，大小为0.65t.p.b的人类基因组DNA区域。 它具有以下遗传标记：基因组ApR确保对氨苄青霉素的抗性，基因组SmR确保对链霉素的抗性; 含有限制性识别区域：Hind III-O; EcoRI-1.4 t.p.b.，BamHI-10.82 t.p.b.它在A11-联合抗生素研究所的微量杂交培养物的收集中保藏，并且在1788I条目下注册。 菌株Pseudomonas Sp。 31（pVN22） - 包含通过遗传工程方法产生的重组质粒DNA pVN22的人白细胞干扰素α-1的生产者，所述重组质粒DNA pVN22通过将所述质粒引入到在A11-细胞的微生物收集培养物中保存的假单胞菌属细菌中， 联合抗生素研究所02.04.86，注册号为1788A。
-
3.发明授权Recombinant proteins of a pakistani strain of hepatitis E and their use in diagnostic methods and vaccines 失效戊型肝炎病毒的重组蛋白及其在诊断方法和疫苗中的应用公开(公告)号：US06787145B1
公开(公告)日：2004-09-07
申请号：US09724475
申请日：2000-11-28
IPC分类号： A61K3929
CPC分类号： C12N15/1131 , A61K38/00 , A61K39/00 , C07H21/00 , C07K14/005 , C12N7/00 , C12N2310/3125 , C12N2310/314 , C12N2310/315 , C12N2310/321 , C12N2310/341 , C12N2310/345 , C12N2310/346 , C12N2710/14143 , C12N2770/28122 , C12N2770/28123 , Y10S436/82 , C12N2310/3521
摘要： A strain of hepatitis E virus from Pakistan (SAR-55) implicated in an epidemic of enterically transmitted non-A, non-B hepatitis, now called hepatitis E, is disclosed. The invention relates to the expression of the whole structural region of SAR-55, designated open reading frame 2 (ORF-2), in a eukaryotic expression system. The expressed protein is capable of forming HEV virus-like particles which can serve as an antigen in diagnostic immunoassays and as an immunogen or vaccine to protect against infection by hepatitis E.
摘要翻译： 披露了一种来自巴基斯坦的丙型肝炎病毒（SAR-55），涉及到目前被称为戊型肝炎的非传染性非乙型肝炎的流行病。 本发明涉及真核表达系统中SAR-55整体结构域的表达，其命名为开放阅读框架2（ORF-2）。 表达的蛋白质能够形成HEV病毒样颗粒，其可以在诊断免疫测定中作为抗原，并作为免疫原或疫苗以防止乙型肝炎感染。
-
4.发明授权Recombinant proteins of a Pakistani strain of hepatitis E and their use in diagnostic methods and vaccines 失效巴基斯坦戊型肝炎病毒的重组蛋白及其在诊断方法和疫苗中的应用公开(公告)号：US06696242B1
公开(公告)日：2004-02-24
申请号：US08470246
申请日：1995-06-06
IPC分类号： C12Q170
CPC分类号： C12N15/1131 , A61K38/00 , A61K39/00 , C07H21/00 , C07K14/005 , C12N7/00 , C12N2310/3125 , C12N2310/314 , C12N2310/315 , C12N2310/321 , C12N2310/341 , C12N2310/345 , C12N2310/346 , C12N2710/14143 , C12N2770/28122 , C12N2770/28123 , Y10S436/82 , C12N2310/3521
摘要： A strain of hepatitis E virus from Pakistan (SAR-55) implicated in an epidemic of enterically transmitted non-A, non-B hepatitis, now called hepatitis E, is disclosed. The invention relates to the expression of the whole structural region of SAR-55, designated open reading frame 2 (ORF-2), in a eukaryotic expression system. The expressed protein is capable of forming HEV virus-like particles which can serve as an antigen in diagnostic immunoassays and as an immunogen or vaccine to protect against infection by hepatitis E.
摘要翻译： 披露了一种来自巴基斯坦的丙型肝炎病毒（SAR-55），涉及到目前被称为戊型肝炎的非传染性非乙型肝炎的流行病。 本发明涉及真核表达系统中SAR-55整体结构域的表达，其命名为开放阅读框架2（ORF-2）。 表达的蛋白质能够形成HEV病毒样颗粒，其可以在诊断免疫测定中作为抗原，并作为免疫原或疫苗以防止乙型肝炎感染。
-
5.发明授权Recombinant proteins of a Pakistani strain of hepatitis E and their use in diagnostic methods and vaccines 有权巴基斯坦戊型肝炎病毒的重组蛋白及其在诊断方法和疫苗中的应用公开(公告)号：US06458562B1
公开(公告)日：2002-10-01
申请号：US09402776
申请日：2000-02-22
IPC分类号： C12N1551
CPC分类号： C07K14/005 , C12N2770/28122 , Y10S977/804
摘要： The invention relates to the expression of open reading frame 2 (ORF-2) proteins of a strain of hepatitis E virus from Pakistan (SAR-55) in a eukaryotic expression system. The expressed proteins can serve as an antigen in diagnostic immunoassays and/or as an immunogen or vaccine to protect against infection by hepatitis E.
摘要翻译： 本发明涉及在真核表达系统中来自巴基斯坦（SAR-55）的乙型肝炎病毒株的开放阅读框2（ORF-2）蛋白的表达。 表达的蛋白质可以用作诊断免疫测定中的抗原和/或作为免疫原或疫苗以防止乙型肝炎的感染。
-
公开(公告)号：US06287759B1
公开(公告)日：2001-09-11
申请号：US08471971
申请日：1995-06-06
IPC分类号： C12Q170
CPC分类号： C07K14/005 , A61K38/00 , A61K39/00 , C07H21/00 , C12N7/00 , C12N15/1131 , C12N2310/3125 , C12N2310/314 , C12N2310/315 , C12N2310/321 , C12N2310/341 , C12N2310/345 , C12N2310/346 , C12N2710/14143 , C12N2770/28021 , C12N2770/28022 , C12N2770/28122 , C12N2770/28123 , Y10S977/802 , C12N2310/3521
摘要： A strain of hepatitis E virus from Pakistan (SAR-55) implicated in an epidemic of enterically transmitted non-A, non-B hepatitis, now called hepatitis E, is disclosed. The invention relates to the expression of the whole structural region of SAR-55, designated open reading frame 2 (ORF-2), in a eukaryotic expression system. The expressed protein is capable of forming HEV virus-like particles which can serve as an antigen in diagnostic immunoassays and as an immunogen or vaccine to protect against infection by hepatitis E.
-
7.发明授权Recombinant proteins of a Pakistani strain of hepatitis E and their use in diagnostic methods and vaccines 失效巴基斯坦戊型肝炎病毒的重组蛋白及其在诊断方法和疫苗中的应用公开(公告)号：US06207416B1
公开(公告)日：2001-03-27
申请号：US08809523
申请日：1997-05-28
IPC分类号： C12N1551
CPC分类号： C07H21/00 , A61K38/00 , A61K39/00 , C07K14/005 , C12N7/00 , C12N15/1131 , C12N2310/3125 , C12N2310/314 , C12N2310/315 , C12N2310/321 , C12N2310/341 , C12N2310/345 , C12N2310/346 , C12N2710/14143 , C12N2770/28021 , C12N2770/28022 , C12N2770/28122 , C12N2770/28123 , C12N2310/3521
摘要： A strain of hepatitis E virus from Pakistan (SAR-55) implicated in an epidemic of enterically transmitted non-A, non-B hepatitis, now called hepatitis E, is disclosed. The invention relates to the expression of the whole structural region of SAR-55, designated open reading frame 2 (ORF-2), in a eukaryotic expression system. The expressed protein is capable of forming HEV virus-like particles which can serve as an antigen in diagnostic immunoassays and as an immunogen or vaccine to protect against infection by hepatitis E.
摘要翻译： 披露了一种来自巴基斯坦的丙型肝炎病毒（SAR-55），涉及到目前被称为戊型肝炎的非传染性非乙型肝炎的流行病。 本发明涉及真核表达系统中SAR-55整体结构域的表达，其命名为开放阅读框架2（ORF-2）。 表达的蛋白质能够形成HEV病毒样颗粒，其可以在诊断免疫测定中作为抗原，并作为免疫原或疫苗以防止乙型肝炎感染。
-
公开(公告)号：US4680260A
公开(公告)日：1987-07-14
申请号：US751798
申请日：1985-07-03
申请人： Vladimir G. Debabov , Jury D. Tsygankov , Andrei J. Chistoserdov , Evgeny D. Sverdlov , Lara S. Izotova , Sergei V. Kostrov , Viktor E. Sterkin , Vladimir P. Kuznetsov , Sergei V. Belyaev , Galina S. Monastyrskaya , Irina S. Salomatina , Grigory M. Dolganov , Sergei G. Arsenian , Sergei A. Tsarev , Jury I. Kozlov , Alexandr Y. Strongin , Vsevolod I. Ogarkov , Jury A. Ovchinnikov
发明人： Vladimir G. Debabov , Jury D. Tsygankov , Andrei J. Chistoserdov , Evgeny D. Sverdlov , Lara S. Izotova , Sergei V. Kostrov , Viktor E. Sterkin , Vladimir P. Kuznetsov , Sergei V. Belyaev , Galina S. Monastyrskaya , Irina S. Salomatina , Grigory M. Dolganov , Sergei G. Arsenian , Sergei A. Tsarev , Jury I. Kozlov , Alexandr Y. Strongin , Vsevolod I. Ogarkov , Jury A. Ovchinnikov
CPC分类号： C07K14/56 , C12N15/78 , Y10S435/811 , Y10S930/142
摘要： A method for producing human leukocyte interferon alpha-2 resides in that there is carried out submerged cultivation of a producer strain Pseudomonas species VG-84 carrying a plasmid pVG3 with an inserted gene of human leukocyte interferon alpha-2, said strain being deposited in the collection of microorganism cultures at the USSR Antibiotics Research Institute under Reg. No. 1742; said strain being cultivated in a nutrient medium, containing the sources of carbon and nitrogen, mineral salts and growth stimulants, under aeration in the presence of antibiotics, i.e., streptomycin or tetracycline, or a mixture of both, followed by isolation and purification of the end product.
摘要翻译： 生产人白细胞干扰素α-2的方法在于，进行了携带具有人白细胞干扰素α-2插入基因的质粒pVG3的产生菌假单胞菌属物种VG-84的浸没培养，所述菌株沉积在 在苏联抗生素研究所收集微生物培养物。 第1742号 所述菌株在含有碳和氮源，矿物盐和生长兴奋剂的营养培养基中培养，在抗生素即链霉素或四环素或两者的混合物的通风下通气，然后分离和纯化 成品。
-
公开(公告)号：US06706873B1
公开(公告)日：2004-03-16
申请号：US08316765
申请日：1994-10-03
IPC分类号： C07H2104
CPC分类号： C07K14/005 , A61K38/00 , A61K39/00 , C07H21/00 , C12N7/00 , C12N15/1131 , C12N2310/3125 , C12N2310/314 , C12N2310/315 , C12N2310/321 , C12N2310/341 , C12N2310/345 , C12N2310/346 , C12N2710/14143 , C12N2770/28021 , C12N2770/28022 , C12N2770/28122 , C12N2770/28123 , Y10S977/802 , C12N2310/3521
摘要： A strain of hepatitis E virus from Pakistan (SAR-55) implicated in an epidemic of enterically transmitted non-A, non-B hepatitis, now called hepatitis E, is disclosed. The invention relates to the expression of the whole structural region of SAR-55, designated open reading frame 2 (ORF-2), in a eukaryotic expression system. The expressed protein is capable of forming HEV virus-like particles which can serve as an antigen in diagnostic immunoassays and as an immunogen or vaccine to protect against infection by hepatitis E.
-
公开(公告)号：US6146643A
公开(公告)日：2000-11-14
申请号：US473185
申请日：1995-06-07
CPC分类号： C07K14/005 , C12N7/00 , A61K39/00 , C12N2770/32422 , C12N2770/32434 , C12N2770/32461 , Y10S530/825
摘要： The present invention relates, in general, to a substantially pure preparation of the simian hepatitis A viral isolate AGM-27; a substantially pure preparation of the genomic DNA of simian hepatitis A viral isolate AGM-27; a pharmaceutical composition comprising the simian hepatitis A viral isolate AGM-27; a method of preventing hepatitis A in an animal; and a vaccine comprising the simian hepatitis A viral isolate AGM-27.
摘要翻译： 本发明一般涉及猿猴甲型肝炎病毒分离物AGM-27的基本上纯的制剂; 猿猴甲型肝炎病毒分离株AGM-27的基因组DNA基本上纯的制剂; 包含猿猴甲型肝炎病毒分离物AGM-27的药物组合物; 预防动物中甲型肝炎的方法; 和包含猿猴甲型肝炎病毒分离物AGM-27的疫苗。
-
-
-
-
-
-
-
-
-
搜索结果
11 条记录 (耗时 0.028 秒)
